The U.S. Food and Drug Administration (FDA) approved belumosudil on July 16, 2021.

Skyhawk Therapeutics Reports Positive Topline Results from Phase 1 Trial of SKY-0515 for Huntington’s Disease, Achieving 72% Reduction in Huntingtin mRNA.

The U.S. Food and Drug Administration (FDA) approved finerenone on July 9, 2021.

MEKanistic Therapeutics Inc.’s innovative dual-target therapy, MTX-531, shows considerable tolerability and sustained tumor reduction in preclinical cancer studies.

Aducanumab, sold under the brand name Aduhelm, is an intravenous medication used to treat Alzheimer's disease. Aducanumab was approved by the U.S. Food and Drug Administration (FDA) on June 7, 2021.

Rgenta Therapeutics secures FDA nod for IND application of RGT-61159, an oral RNA modulator intended to stop MYB production, targeting Adenoid Cystic Carcinoma (ACC) and Colorectal Cancer (CRC).

Ryplazim was approved by the U.S. Food and Drug Administration (FDA) on June 4, 2021. This approval marked a significant milestone as Ryplazim is the first therapy approved for treating plasminogen deficiency type 1.

Avalo Therapeutics Reports IND Activation for AVTX-009, an anti-IL-1β Antibody, Aimed at Treating Hidradenitis Suppurativa.

Tembexa (brincidofovir) was approved by the U.S. Food and Drug Administration (FDA) on June 4, 2021.

uniQure Releases Promising Interim Results Showing Reduced Disease Progression in Phase I/II AMT-130 Trials for Huntington’s Disease.

Brexafemme (ibrexafungerp) was approved by the U.S. Food and Drug Administration (FDA) on June 1, 2021.

The agreement specifies that the Phase 2 clinical trial will evaluate the effectiveness of PRT37890, a new and highly selective SMARCA2 degrader, and Merck's KEYTRUDA in treating cancers with SMARCA4 mutations.